PWMG
TGTX icon

Prestige Wealth Management Group’s TG Therapeutics TGTX Stock Holding History

Prestige Wealth Management Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26K Buy
23
+16
+229% +$655 ﹤0.01% 845
2026
Q1 		$233 Sell
7
-43
-86% -$1.28K ﹤0.01% 1063
2025
Q4 		$1.49K Hold
50
– – ﹤0.01% 812
2025
Q3 		$1.81K Hold
50
– – ﹤0.01% 763
2025
Q2 		$1.8K Hold
50
– – ﹤0.01% 758
2025
Q1 		$1.97K Sell
50
-50
-50% -$1.68K ﹤0.01% 742
2024
Q4 		$3.01K Hold
100
– – ﹤0.01% 699
2024
Q3 		$2.34K Buy
+100
New +$2.18K ﹤0.01% 743

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Prestige Wealth Management Group's TGTX Position: Q2 2026 in Review

Prestige Wealth Management Group increased its TG Therapeutics (TGTX) stake by 229% in Q2 2026, buying an estimated $655 and bringing the position to 23 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #845.

Prestige Wealth Management Group first reported a position in TGTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.01K in Q4 2024. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Prestige Wealth Management Group held 23 shares of TG Therapeutics worth $1.26K as of Q2 2026.
  • Prestige Wealth Management Group bought 16 TG Therapeutics shares in Q2 2026, an estimated $655.
  • TG Therapeutics made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #845 holding.
  • Prestige Wealth Management Group first reported a position in TG Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Prestige Wealth Management Group's TG Therapeutics position peaked at $3.01K in Q4 2024.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.